

CORRIGENDUM

Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’



[ESMO Open Volume 6, Issue 2, April 2021, 100054]

C. De Angelis¹, D. Bruzzese², A. Bernardo³, E. Baldini⁴, L. Leo⁵, A. Fabi⁶, T. Gamucci⁷, P. De Placido¹, F. Poggio⁸, S. Russo⁹, V. Forestieri¹, R. Lauria¹, I. De Santo¹, R. Caputo¹⁰, D. Cianniello¹⁰, A. Michelotti¹¹, L. Del Mastro^{8,12}, M. De Laurentiis¹⁰, M. Giuliano^{1*}, S. De Placido¹ & G. Arpino¹

¹Department of Clinical Medicine and Surgery, University of Naples “Federico II”, Naples; ²Department of Public Health, University of Naples “Federico II”, Naples; ³Oncologia Medica, Fondazione S. Maugeri IRCCS, Pavia; ⁴Department of Oncology, S. Luca Hospital, Lucca; ⁵Unit of Oncology, A.O.R.N. dei Colli, Napoli, Naples; ⁶Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome; ⁷Medical Oncology Unit, ASL Frosinone, Frosinone; ⁸UO Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova; ⁹Department of Oncology, Azienda Sanitaria Universitaria Integrata di Udine, Udine; ¹⁰Breast Oncology Department, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy; ¹¹Azienda Ospedaliera Universitaria Pisana, Ospedale Santa Chiara, Pisa; ¹²University of Genova, Dipartimento di Medicina Interna e Specialità Mediche (DIMI), Genova, Italy

The authors regret that at the time the article was published the following two authors were missing from the author list: R. Caputo and D. Cianniello. Both authors affiliation is the Breast Oncology Department, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy. The updated author list is as follows:

C. De Angelis, D. Bruzzese, A. Bernardo, E. Baldini, L. Leo, A. Fabi, T. Gamucci, P. De Placido, F. Poggio, S. Russo, V. Forestieri, R. Lauria, I. De Santo, R. Caputo, D. Cianniello, A. Michelotti, L. Del Mastro, M. De Laurentiis, M. Giuliano, S. De Placido, G. Arpino.

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.esmoop.2021.100054>

*Correspondence to: M. Giuliano.

E-mail: m.giuliano@unina.it (M. Giuliano).

2059-7029/© 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. All rights reserved.